The dual role of NSD2 in mitochondrial function: Insights into interstitial fibrosis and renal cancer

被引：0
|
作者：
Huang, Chien-Wei [1 ,2 ]
Wen, Chen-Yueh [3 ]
Chen, Po-Hung [4 ]
Yong, Su-Boon [5 ,6 ]
Chen, Jin-Shuen [7 ,8 ]
Li, Chia-Jung [9 ,10 ]
机构：
[1] Kaohsiung Vet Gen Hosp, Dept Internal Med, Div Nephrol, Kaohsiung 813, Taiwan
[2] Natl Yang Ming Chiao Tung Univ, Sch Med, Taipei 112, Taiwan
[3] Show Chwan Mem Hosp, Div Urol, Changhua 500, Taiwan
[4] Kaohsiung Municipal Minsheng Hosp, Dept Emergency Med, Kaohsiung 802, Taiwan
[5] China Med Univ Childrens Hosp, Dept Allergy & Immunol, Taichung 404, Taiwan
[6] China Med Univ Hosp, Res Ctr Allergy Immunol & Microbiome AIM, Taichung 404, Taiwan
[7] Kaohsiung Vet Gen Hosp, Dept Adm, Kaohsiung 813, Taiwan
[8] Natl Sun Yat Sen Univ, Inst Precis Med, Kaohsiung 804, Taiwan
[9] Kaohsiung Vet Gen Hosp, Dept Obstet & Gynaecol, Kaohsiung 813, Taiwan
[10] Natl Sun Yat Sen Univ, Inst BioPharmaceut Sci, Kaohsiung 804, Taiwan
来源：
PHARMACOLOGICAL RESEARCH | 2024年 / 207卷
关键词：
D O I：
10.1016/j.phrs.2024.107320
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] NSD2 modulates Drp1-mediated mitochondrial fission in chronic renal allograft interstitial fibrosis by methylating STAT1
    Zhang, Jianjian
    Xie, Weibin
    Ni, Bin
    Li, Zhuohang
    Feng, Dengyuan
    Zhang, Yao
    Han, Qianguang
    Zhou, Hai
    Gu, Min
    Tan, Ruoyun
    PHARMACOLOGICAL RESEARCH, 2024, 200
  • [2] METTL3 enhances NSD2 mRNA stability to reduce renal impairment and interstitial fibrosis in mice with diabetic nephropathy
    Tang, Weiming
    Zhao, Yilin
    Zhang, Hui
    Peng, Ying
    Rui, Zhilian
    BMC NEPHROLOGY, 2022, 23 (01)
  • [3] METTL3 enhances NSD2 mRNA stability to reduce renal impairment and interstitial fibrosis in mice with diabetic nephropathy
    Weiming Tang
    Yilin Zhao
    Hui Zhang
    Ying Peng
    Zhilian Rui
    BMC Nephrology, 23
  • [4] NSD2 Promotes Renal Cancer Progression Through Stimulating Akt/Erk Signaling
    Han, Xu
    Piao, Lianhua
    Xu, Xiaoshuang
    Luo, Fengbao
    Liu, Zhiwei
    He, Xiaozhou
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 375 - 383
  • [5] The role of NSD1, NSD2, and NSD3 histone methyltransferases in solid tumors
    Iuliia Topchu
    Rajendra P. Pangeni
    Igor Bychkov
    Sven A. Miller
    Evgeny Izumchenko
    Jindan Yu
    Erica Golemis
    John Karanicolas
    Yanis Boumber
    Cellular and Molecular Life Sciences, 2022, 79
  • [6] The role of NSD1, NSD2, and NSD3 histone methyltransferases in solid tumors
    Topchu, Iuliia
    Pangeni, Rajendra P.
    Bychkov, Igor
    Miller, Sven A.
    Izumchenko, Evgeny
    Yu, Jindan
    Golemis, Erica
    Karanicolas, John
    Boumber, Yanis
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2022, 79 (06)
  • [7] THE ROLE OF NSD2 AND EZH2 IN THE PATHOGENESIS OF ENDOMETRIAL CARCINOMA
    Sun, S.
    Huang, D. W.
    Huo, L. T.
    Li, P. L.
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2019, 33 (04): : 1233 - 1239
  • [8] A rational approach for the discovery of inhibitors of NSD2 for the treatment of cancer
    Fromond, Claudia
    Espanel, Xavier
    Boude, Anne
    Chene, Laurent
    Masson, Philippe
    Boubia, Benaissa
    Montalbetti, Christian
    Broqua, Pierre
    CANCER RESEARCH, 2015, 75
  • [9] NSD2 is a conserved driver of metastatic prostate cancer progression
    Aytes, Alvaro
    Giacobbe, Arianna
    Mitrofanova, Antonina
    Ruggero, Katia
    Cyrta, Joanna
    Arriaga, Juan
    Palomero, Luis
    Farran-Matas, Sonia
    Rubin, Mark A.
    Shen, Michael M.
    Califano, Andrea
    Abate-Shen, Cory
    NATURE COMMUNICATIONS, 2018, 9
  • [10] NSD2 is a conserved driver of metastatic prostate cancer progression
    Alvaro Aytes
    Arianna Giacobbe
    Antonina Mitrofanova
    Katia Ruggero
    Joanna Cyrta
    Juan Arriaga
    Luis Palomero
    Sonia Farran-Matas
    Mark A. Rubin
    Michael M. Shen
    Andrea Califano
    Cory Abate-Shen
    Nature Communications, 9
12345